Published in Leuk Lymphoma on October 01, 2006
Primary extranodal lymphomas of stomach: clinical presentation, diagnostic pitfalls and management. Ann Oncol (2008) 1.64
Therapy of gastric mucosa associated lymphoid tissue lymphoma. World J Gastroenterol (2007) 0.91
Hematologic manifestations of Helicobacter pylori infection. World J Gastroenterol (2014) 0.83
Thoughts on the eradication of Helicobacter pylori infection in localized gastric mucosa-associated lymphoid tissue lymphoma. Leuk Lymphoma (2006) 0.77
A Gain-Of-Function Mutation in the Plcg2 Gene Protects Mice from Helicobacter felis-Induced Gastric MALT Lymphoma. PLoS One (2016) 0.76
Prevalence of Barrett's esophagus in the general population: an endoscopic study. Gastroenterology (2005) 5.77
Methylene blue-aided chromoendoscopy for the detection of intraepithelial neoplasia and colon cancer in ulcerative colitis. Gastroenterology (2003) 5.11
Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV. J Clin Oncol (2013) 4.50
Curative endoscopic resection of early esophageal adenocarcinomas (Barrett's cancer). Gastrointest Endosc (2007) 4.28
Chromoscopy-guided endomicroscopy increases the diagnostic yield of intraepithelial neoplasia in ulcerative colitis. Gastroenterology (2007) 4.09
In vivo histology of Barrett's esophagus and associated neoplasia by confocal laser endomicroscopy. Clin Gastroenterol Hepatol (2006) 3.69
Cardiac rather than intestinal-type background in endoscopic resection specimens of minute Barrett adenocarcinoma. Hum Pathol (2008) 3.27
Helicobacter pylori as a prognostic indicator after curative resection of gastric carcinoma: a prospective study. Lancet Oncol (2006) 3.18
Ablation of nonneoplastic Barrett's mucosa using argon plasma coagulation with concomitant esomeprazole therapy (APBANEX): a prospective multicenter evaluation. Am J Gastroenterol (2006) 3.11
Compassionate use of sorafenib in FLT3-ITD-positive acute myeloid leukemia: sustained regression before and after allogeneic stem cell transplantation. Blood (2009) 2.82
A prospective randomized trial of two different endoscopic resection techniques for early stage cancer of the esophagus. Gastrointest Endosc (2003) 2.47
Budesonide is effective in treating lymphocytic colitis: a randomized double-blind placebo-controlled study. Gastroenterology (2009) 2.16
High prevalence of gastroesophageal reflux symptoms and esophagitis with or without symptoms in the general adult Swedish population: a Kalixanda study report. Scand J Gastroenterol (2005) 2.13
Risk factors for erosive esophagitis: a multivariate analysis based on the ProGERD study initiative. Am J Gastroenterol (2004) 2.09
Effects of Helicobacter pylori eradication on early stage gastric mucosa-associated lymphoid tissue lymphoma. Clin Gastroenterol Hepatol (2009) 2.09
T(11;18) is a marker for all stage gastric MALT lymphomas that will not respond to H. pylori eradication. Gastroenterology (2002) 2.06
Sustained molecular response with interferon alfa maintenance after induction therapy with imatinib plus interferon alfa in patients with chronic myeloid leukemia. J Clin Oncol (2010) 1.98
Prevalence of oesophageal eosinophils and eosinophilic oesophagitis in adults: the population-based Kalixanda study. Gut (2006) 1.92
Low BCR-ABL expression levels in hematopoietic precursor cells enable persistence of chronic myeloid leukemia under imatinib. Blood (2011) 1.81
Budesonide treatment for collagenous colitis: a randomized, double-blind, placebo-controlled, multicenter trial. Gastroenterology (2002) 1.72
Long-term follow-up of gastric MALT lymphoma after Helicobacter pylori eradication. J Clin Oncol (2005) 1.72
T(14;18)(q32;q21) involving IGH and MALT1 is a frequent chromosomal aberration in MALT lymphoma. Blood (2002) 1.71
Allele 2 of the interleukin-1 receptor antagonist gene is associated with early gastric cancer. J Clin Oncol (2004) 1.70
Gastric MALT lymphoma B cells express polyreactive, somatically mutated immunoglobulins. Blood (2009) 1.68
Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV. Blood (2011) 1.65
Peptic ulcer disease in a general adult population: the Kalixanda study: a random population-based study. Am J Epidemiol (2006) 1.64
Prospective follow-up data from the ProGERD study suggest that GERD is not a categorial disease. Am J Gastroenterol (2006) 1.62
High-dose cytarabine consolidation with or without additional amsacrine and mitoxantrone in acute myeloid leukemia: results of the prospective randomized AML2003 trial. J Clin Oncol (2013) 1.60
Diagnosing Helicobacter pylori in vivo by confocal laser endoscopy. Gastroenterology (2005) 1.59
The optimal dose of 5-aminosalicylic acid in active ulcerative colitis: a dose-finding study with newly developed mesalamine. Clin Gastroenterol Hepatol (2003) 1.56
Treatment with ozone/oxygen-pneumoperitoneum results in complete remission of rabbit squamous cell carcinomas. Int J Cancer (2008) 1.51
Juvenile polyposis: massive gastric polyposis is more common in MADH4 mutation carriers than in BMPR1A mutation carriers. Hum Genet (2002) 1.50
Circumferential EMR and complete removal of Barrett's epithelium: a new approach to management of Barrett's esophagus containing high-grade intraepithelial neoplasia and intramucosal carcinoma. Gastrointest Endosc (2003) 1.49
Early Barrett's carcinoma with "low-risk" submucosal invasion: long-term results of endoscopic resection with a curative intent. Am J Gastroenterol (2008) 1.47
Sorafenib in combination with intensive chemotherapy in elderly patients with acute myeloid leukemia: results from a randomized, placebo-controlled trial. J Clin Oncol (2013) 1.46
Evaluation of sensitivity and inter- and intra-observer variability in the detection of intestinal metaplasia and dysplasia in Barrett's esophagus with enhanced magnification endoscopy. Scand J Gastroenterol (2006) 1.45
Intensified double induction therapy with high dose mitoxantrone, etoposide, m-amsacrine and high dose ara-C for elderly acute myeloid leukemia patients aged 61-65 years. Haematologica (2002) 1.42
Effect of esomeprazole triple therapy on eradication rates of Helicobacter pylori, gastric ulcer healing and prevention of relapse in gastric ulcer patients. Eur J Gastroenterol Hepatol (2008) 1.42
Comparison of ATP-binding cassette transporter interactions with the tyrosine kinase inhibitors imatinib, nilotinib, and dasatinib. Drug Metab Dispos (2010) 1.41
Primary follicular lymphoma of the duodenum is a distinct mucosal/submucosal variant of follicular lymphoma: a retrospective study of 63 cases. J Clin Oncol (2011) 1.41
Clinical trial of valproic acid and all-trans retinoic acid in patients with poor-risk acute myeloid leukemia. Cancer (2005) 1.38
Efficacy, safety, and long-term results of endoscopic treatment for early stage adenocarcinoma of the esophagus with low-risk sm1 invasion. Clin Gastroenterol Hepatol (2013) 1.33
Confocal laser endomicroscopy for in vivo diagnosis of early squamous cell carcinoma in the esophagus. Clin Gastroenterol Hepatol (2007) 1.31
miR-10a overexpression is associated with NPM1 mutations and MDM4 downregulation in intermediate-risk acute myeloid leukemia. Exp Hematol (2011) 1.27
Gastric-type well-differentiated adenocarcinoma and pyloric gland adenoma of the stomach. Gastric Cancer (2006) 1.26
A negative Helicobacter pylori serology test is more reliable for exclusion of premalignant gastric conditions than a negative test for current H. pylori infection: a report on histology and H. pylori detection in the general adult population. Scand J Gastroenterol (2005) 1.26
Oral budesonide for maintenance treatment of collagenous colitis: a randomized, double-blind, placebo-controlled trial. Gastroenterology (2008) 1.25
Interferon consensus sequence binding protein (ICSBP; IRF-8) antagonizes BCR/ABL and down-regulates bcl-2. Blood (2003) 1.22
Identification of non-Helicobacter pylori spiral organisms in gastric samples from humans, dogs, and cats. J Clin Microbiol (2005) 1.15
Long-term results of photodynamic therapy with 5-aminolevulinic acid for superficial Barrett's cancer and high-grade intraepithelial neoplasia. Gastrointest Endosc (2005) 1.15
Helicobacter pylori cag-Pathogenicity island-dependent early immunological response triggers later precancerous gastric changes in Mongolian gerbils. PLoS One (2009) 1.14
Serum biomarkers provide an accurate method for diagnosis of atrophic gastritis in a general population: The Kalixanda study. Scand J Gastroenterol (2008) 1.14
Gastric-type adenocarcinoma of the duodenal second portion histogenetically associated with hyperplasia and gastric-foveolar metaplasia of Brunner's glands. Virchows Arch (2002) 1.13
Follow-up endoscopy in gastroenterology: when is it helpful? Dtsch Arztebl Int (2010) 1.13
Barrett's esophagus: histopathologic definitions and diagnostic criteria. World J Surg (2004) 1.10
Normal intrinsic Th1/Th2 balance in patients with chronic phase chronic myeloid leukemia not treated with interferon-alpha or imatinib. Haematologica (2003) 1.09
Endoscopic resection of superficial esophageal squamous-cell carcinomas: Western experience. Am J Gastroenterol (2004) 1.09
Randomized trial on 14 versus 7 days of esomeprazole, moxifloxacin, and amoxicillin for second-line or rescue treatment of Helicobacter pylori infection. Helicobacter (2011) 1.09
Activation of the RAS pathway is predictive for a chemosensitive phenotype of acute myelogenous leukemia blasts. Clin Cancer Res (2005) 1.04
Why is the hyperplastic polyp a marker for the precancerous condition of the gastric mucosa? Virchows Arch (2005) 1.02
Mutations of BRAF and KRAS2 in the development of Barrett's adenocarcinoma. Oncogene (2004) 1.02
Early involvement of death-associated protein kinase promoter hypermethylation in the carcinogenesis of Barrett's esophageal adenocarcinoma and its association with clinical progression. Neoplasia (2007) 1.01
Pyloric gland adenoma arising in Barrett's esophagus with mucin immunohistochemical and molecular cytogenetic evaluation. Virchows Arch (2005) 1.01
Oncogenic RAS enables DNA damage- and p53-dependent differentiation of acute myeloid leukemia cells in response to chemotherapy. PLoS One (2009) 1.01
Interferon regulatory factor-8 is indispensable for the expression of promyelocytic leukemia and the formation of nuclear bodies in myeloid cells. J Biol Chem (2006) 1.00
The frequency of lymph node metastasis in early-stage adenocarcinoma of the esophagus with incipient submucosal invasion (pT1b sm1) depending on histological risk patterns. Surg Endosc (2014) 1.00
Boswellia serrata extract for the treatment of collagenous colitis. A double-blind, randomized, placebo-controlled, multicenter trial. Int J Colorectal Dis (2007) 0.99
Pathology of early upper GI cancers. Best Pract Res Clin Gastroenterol (2005) 0.99
Association of body mass index with heartburn, regurgitation and esophagitis: results of the Progression of Gastroesophageal Reflux Disease study. J Gastroenterol Hepatol (2007) 0.99
Younger patients with chronic myeloid leukemia do well in spite of poor prognostic indicators: results from the randomized CML study IV. Ann Hematol (2013) 0.98
Is there an association of microscopic colitis and irritable bowel syndrome--a subgroup analysis of placebo-controlled trials. World J Gastroenterol (2005) 0.97
A variant allele of Growth Factor Independence 1 (GFI1) is associated with acute myeloid leukemia. Blood (2010) 0.96
Conditioning with 8-Gy total body irradiation and fludarabine for allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia. Blood (2005) 0.96
MicroRNA29a regulates the expression of the nuclear oncogene Ski. Blood (2011) 0.94
Role of tumor necrosis factor alpha in Helicobacter pylori gastritis in tumor necrosis factor receptor 1-deficient mice. Infect Immun (2002) 0.94
Long-term results of endoscopic resection in early gastric cancer: the Western experience. Am J Gastroenterol (2009) 0.94
Oral budesonide therapy improves quality of life in patients with collagenous colitis. Int J Colorectal Dis (2004) 0.93
One-week once-daily triple therapy with esomeprazole, moxifloxacin, and rifabutin for eradication of persistent Helicobacter pylori resistant to both metronidazole and clarithromycin. Helicobacter (2008) 0.93
7-day triple therapy of Helicobacter pylori infection with levofloxacin, amoxicillin, and high-dose esomeprazole in patients with known antimicrobial sensitivity. Helicobacter (2006) 0.93
Dexamethasone, high-dose cytarabine, and cisplatin in combination with rituximab as salvage treatment for patients with relapsed or refractory aggressive non-Hodgkin's lymphoma. Cancer Invest (2006) 0.92
B-cell monoclonality is associated with lymphoid follicles in gastritis. Am J Surg Pathol (2003) 0.92
Treatment of HNSCC cell lines with the EGFR-specific inhibitor cetuximab (Erbitux) results in paradox phosphorylation of tyrosine 1173 in the receptor. FEBS Lett (2006) 0.92
Cytokeratin 7/20 and mucin core protein expression in ulcerative colitis-associated colorectal neoplasms. Virchows Arch (2006) 0.92
Correlation of serum pepsinogens and gastrin-17 with atrophic gastritis in gastroesophageal reflux patients: a matched-pairs study. J Gastroenterol Hepatol (2011) 0.91
Down-regulation of interferon regulatory factor 4 gene expression in leukemic cells due to hypermethylation of CpG motifs in the promoter region. Nucleic Acids Res (2005) 0.91
Detection of non-pylori Helicobacter species in "Helicobacter heilmannii"-infected humans. Helicobacter (2005) 0.91
DNA copy number profiles of gastric cancer precursor lesions. BMC Genomics (2007) 0.91
Therapy of gastric mucosa associated lymphoid tissue lymphoma. World J Gastroenterol (2007) 0.91
Early Barrett's carcinoma: the depth of infiltration of the tumour correlates with the degree of differentiation, the incidence of lymphatic vessel and venous invasion. Virchows Arch (2010) 0.90